/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-03-24 11:12:002021-03-24 11:12:00Abivax with new CMO
https://european-biotechnology.com/wp-content/uploads/2024/04/T_cell_lymphoma.jpg8001200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-24 09:39:242021-03-24 09:39:24Step Pharma SAS raises €35m in Series B
The future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.
https://european-biotechnology.com/wp-content/uploads/2024/04/EBM.com_Spring_2021_Biovian_kl.jpg7311300Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-23 14:50:002024-04-02 16:20:10AAV vectors from a CDMO that cares about SMEs
The threat caused by the SARS-CoV-2 virus is a global one. Therefore, we have to address the coronavirus pandemic globally, but at least on a European scale. To achieve this, we need not only a vaccination strategy but also a therapy strategy.
Exosome Diagnostics develops biofluid-based molecular diagnostic tests for use in personalized medicine and collaborates with pharmaceutical companies to develop companion diagnostics (CDx).
The German Patent System has been a very patentee-friendly system, in particular for smaller patentees. Enforcement of patents has been relatively easy, affordable and fast.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017spring-ute-kilger.jpg5621000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-23 12:25:002024-04-02 16:20:11Modernisation of patent law – boon or bane for patentees?
https://european-biotechnology.com/wp-content/uploads/2024/04/Impfung.jpg5641156Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-03-23 07:19:002021-03-23 07:19:00AZD1222 claims 79% effecacy in pivotal US study
On Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.
Three fast-spreading new variants of SARS-CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.
Abivax with new CMO
AppointmentsAt the beginning of March, Dr Sophie Biguenet has been the new Chief Medical Officer of Paris-based Abivax SA.
European Biotechnology Guide 2021
Sponsored PublicationsThe 11th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Step Pharma SAS raises €35m in Series B
Latest NewsKurma Partners-founded Step Pharma has baged €35m in a Series B financing to advance its blood cancer lead STP938.
AAV vectors from a CDMO that cares about SMEs
BackgroundThe future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.
Europe needs a strategy
Latest NewsThe threat caused by the SARS-CoV-2 virus is a global one. Therefore, we have to address the coronavirus pandemic globally, but at least on a European scale. To achieve this, we need not only a vaccination strategy but also a therapy strategy.
IZB Start-up: Exosome Diagnostics
Sponsored PublicationsExosome Diagnostics develops biofluid-based molecular diagnostic tests for use in personalized medicine and collaborates with pharmaceutical companies to develop companion diagnostics (CDx).
Modernisation of patent law – boon or bane for patentees?
BackgroundThe German Patent System has been a very patentee-friendly system, in particular for smaller patentees. Enforcement of patents has been relatively easy, affordable and fast.
AZD1222 claims 79% effecacy in pivotal US study
Latest NewsFollowing assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.
EMA recommends to continue AZD1222 vaccinations
Latest NewsOn Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.
Study COVID-19 variants
ProductsThree fast-spreading new variants of SARS-CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.